KLRS vs REPL vs ADMA

ADMA Biologics, Inc.

(ADMA) offers the better valuation at 13. 7x trailing P/E (9. 9x forward), making it the more compelling value choice. Analysts rate Replimune Group, Inc. (REPL) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +346. 2%, compared to -74. 4% for Replimune Group, Inc. (REPL). Over 10 years, the gap is even starker: ADMA returned +15. 3% versus KLRS's -52. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Kalaris Therapeutics Inc (KLRS) is the lower-risk stock at 0.

81β versus ADMA Biologics, Inc. 's 1. 11β — meaning ADMA is approximately 37% more volatile than KLRS relative to the S&P 500. On balance sheet safety, Kalaris Therapeutics Inc (KLRS) carries a lower debt/equity ratio of 2% versus 18% for Replimune Group, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Kalaris Therapeutics Inc grew EPS 75.

7% year-over-year, compared to -25. 9% for ADMA Biologics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ADMA Biologics, Inc.

(ADMA) is the more profitable company, earning 28. 8% net margin versus 0. 0% for Replimune Group, Inc. — meaning it keeps 28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 37. 5% versus 0. 0% for REPL. At the gross margin level — before operating expenses — ADMA leads at 57. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for KLRS: 331.

2% to $18. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Kalaris Therapeutics Inc (KLRS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

81)). Both have compounded well over 10 years (KLRS: -52. 5%, ADMA: +15. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KLRS is a small-cap quality compounder stock; REPL is a small-cap quality compounder stock; ADMA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.